WO1985002767A1 - Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation - Google Patents
Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation Download PDFInfo
- Publication number
- WO1985002767A1 WO1985002767A1 PCT/EP1984/000417 EP8400417W WO8502767A1 WO 1985002767 A1 WO1985002767 A1 WO 1985002767A1 EP 8400417 W EP8400417 W EP 8400417W WO 8502767 A1 WO8502767 A1 WO 8502767A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- drug
- water
- anyone
- cyclodextrin
- σharaσterized
- Prior art date
Links
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
- C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
- C08B37/0012—Cyclodextrin [CD], e.g. cycle with 6 units (alpha), with 7 units (beta) and with 8 units (gamma), large-ring cyclodextrin or cycloamylose with 9 units or more; Derivatives thereof
- C08B37/0015—Inclusion compounds, i.e. host-guest compounds, e.g. polyrotaxanes
Definitions
- compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation are instable or sparingly soluble in water and methods for their preparation
- the invention relates to pharmaceutical compositions con- taining drugs which are instable or only sparingly soluble in water, and methods for their preparation.
- the compo ⁇ sitions are characterized by increased water solubility and improved stability.
- a large number of drugs is only poorly or sparingly soluble in water so that suitable application forms " like drop solutions or injection solutions are being prepared using other polar additives like propylene glycol etc. If the drug molecule has basic or acidic groups there exists the further possibility of increasing the water solubility by salt formation. As a rule this results in decreased efficacy or impaired chemical stability. Due to the shifted distribution equilibrium the drug may penetrate the lipophilic membrane only slowly corresponding to the concentration of the non-dissociated fraction while the ionic fraction _may be subject to a rapid hydrolytic decomposition.
- inclusion compounds e.g. with ⁇ rea or complexes of polyvinyl pyrrolidone may improve the solubility of a compound but in aqueous solution they are not stable. Such inclusion compounds are therefore at ' best suitable for solid application forms of drugs.
- German Offenlegungsschrift 31 18 218 discloses a solubilization method using methylat- ed ⁇ -cyclodextrin as monomethyl derivative with 7 methyl groups and especially as dimethyl derivative with 14 methyl groups.
- 2,6-di-O-methyl derivative it is for instance possible to increase the water solublity of indometacin 20.4-fold and that of digitoxin 81.6-fold.
- the methyl derivatives of ⁇ -cyclodextrin show serious draw backs.
- compositions comprising inclusion compounds of only sparingly water-soluble and in water instable drugs with a partially etherified ⁇ -cyclodextrin of the formula
- residues R are hydroxyalkyl groups and part of the residues R may optionally be alkyl groups, the ⁇ -cyclodextrin ether having a water-solubility of more than 1.8 g in 100 ml water.
- a partially etherified ⁇ -cyclodextrin of formula I is preferably used in which the residues R are hydroxyethyl, hydroxypropyl or dihydroxypropyl groups.
- the residues R may for instance be methyl or ethyl - 4 -
- Partial ethers of ⁇ -cyclodextrin comprising only alkyl groups may be suitable in accordance with the invention if they have a low degree of substitution (as defined below) of 0.05 to 0.2.
- ⁇ -cyclodextrin is a compound with ring structure consist ⁇ ing of 7 anhydro glucose units; it is also referred to as cycloheptaamylose.
- Each of the 7 glucose rings contains in 2-,3-, and 6-position three hydroxy groups which may be etherified.
- the partially etherified ⁇ -cyclodextrin derivatives used according to the invention only part of these hydroxy groups is etherified with hydroxyalkyl groups and optionally further with alkyl groups.
- the degree of substitution is stated as molar substitution (MS), viz.
- the etherification with alkyl groups may be stated direct- ly as degree of substitution (DS) per glucose unit which - as stated above - is 3 for complete substitution.
- Partial ⁇ ly etherified ⁇ -cyclodextrins are used within the in ⁇ vention which comprise besides hydroxyalkyl groups also alkyl groups, especially " methyl or ethyl groups, up to a degree of substitution of 0.05 to 2.0, preferably 0.2 to 1.5. Most preferably the degree of substitution with alkyl groups is between about 0.5 and about 1.2.
- the molar ratio of drug to ⁇ -cy ⁇ lodextrin ether is preferably about 1:6 to 4:1, especially about 1:2 to 1:1. As a rule it is preferred to use the complex forming agent in a molar excess.
- Useful complex forming agents are especially the hydroxy- ethyl, hydroxypropyl and dihydroxypropyl ether, their corresponding mixed ethers, and further mixed ethers with methyl or ethyl groups, such as methyl-hydroxyethyl, methyl-hydroxypropyl, ethyl-hydroxyethyl and ethyl-hydroxy ⁇ propyl ether of ⁇ -cyclodextrin.
- hydroxyalkyl ethers of ⁇ -cyclo ⁇ dextrin may be carried out using the method of US patent specification 34 59 731. Suitable preparation methods for ⁇ -cyclodextrin ethers may further be found in J. Szejtli et al., Starke 3_2., 165 (1980) und A.P. Croft and R.A. Bartsch, Tetrahedron 3_9_, 1417 (1983).
- Mixed ethers of ⁇ -cyclodextrin can be prepared by reacting ⁇ -cy ⁇ lodextrin in a basic liquid reaction medium comprising an akali metal hydroxide, water and optionally at least one organic solvent (e.g.
- dimethoxyethane or isopropanol with at least two different hydroxyalkylating and optionally al- kylating etherifying agents (e.g. ethylene oxide, propy- lene oxide, methyl or ethyl chloride).
- al- kylating etherifying agents e.g. ethylene oxide, propy- lene oxide, methyl or ethyl chloride.
- Drugs exhibiting a significantly increased water-solubili ⁇ ty and improved stability, respectively, after having been transferred into inclusion compounds with the above- en- tioned ⁇ -cyclodextrin ethers are those having the required shape and size, i.e. which fit into the cavity of the ⁇ -cyclodextrin ring system.
- Benzimidazole derivatives are thiabendazole, fuberi- dazole, oxibendazole, parbendazole, cambendazole, mebenda- zole, fenbendazole, flubendazole, albendazole, oxfenda- zole, nocodazole and astemisole.
- Suitable piperadine deri- vatives are fluspirilene, pimozide, penfluridole, loperamide, astemizole, ketanserine, levocabastine, cisa- pride, altanserine, and ritanserine.
- Suitable piperazine derivatives include lidoflazine, flunarizine, mianserine, oxatomide, mioflazine and cinnarizine.
- suitable imidazole derivatives are metronidazole, ornidazole, ipronidazole, tinidazole, isoconazole, nimora- zole, burimamide, metiamide, metomidate, enilconazole, etomidate, econazole, clotrimazole, carnidazole, cimetidine, docodazole, sulconazole, parconazole, orconazole, butocona- zole, triadiminole, tioconazole, valconazole, fluotrimazole, ketoconazole, oxiconazole, lombazole, bifonazole, oxmeti- dine, fenticonazole and
- compositions are ob ⁇ tained when converting etomidate, ketoconazole, tubulazole, itraconazole, levocabastine or flunarizine into a water-so ⁇ luble form using the complex forming agents of the invention. Such compositions are therefore a special subject of the present invention.
- the invention is further directed to a method of preparing pharmaceutical compositions of sparingly water-soluble or water-instable drugs which is characterized by dissolving the ⁇ -cyclodextrin ether in water and adding thereto the selected drug as well as optionally drying the solution of the formed inclusion compound using methods known per se.
- Formation of the solution may take place at temperatures between 15 and 35 C. - 7 -
- the drug is suitably added batchwise.
- the water may further comprise physiologically compatible compounds such as sodium chloride, potassium nitrate, glucose, mannitole, sorbitol, xylitol or buffers such as phosphate, acetate or citrate buffer.
- ⁇ -cyclodextrin ethers in .accordance with the in ⁇ vention it is possible to prepare application forms of drugs for oral, parenteral or topical application, e.g. infusion and injection solutions, drop solutions (e.g. eye drops or nasal drops), sprays, aerosols, sirups, and medical baths.
- the aqueous solutions may further comprise suitable physio- logically compatible preserving agents such as quarternary ammonium soaps or chlorbutanol.
- the solutions of the inclusion compounds are dried using conventional methods; thus the water may be evaporated in a rotation evaporator or by lyophilisation.
- the residue is pulverized and, optionally after addition of further inert ingre ⁇ washers, converted into uncoated or coated tablets, supposi ⁇ tories, capsules, creams or ointments.
- the phosphate buffer solution mentioned in the examples had a pH of 6.6 and the following composition:
- Figures 1, 3 and 4 show the increase of the drug concentration in solution in relation to the concentration of the complex forming agent for indometacin (figure 1) , piroxicam (figure 3) and dia'zepam (figure 4) .
- the maximum drug concentration is limited by the saturation solubility of the cyclodextrin derivative in the buffer which in case of hydroxyethyl- ⁇ -cyclodextrin (MS 0.43) is reached at 7.2 g/100 ml.
- hydroxypropyl- ⁇ -cyclodextrin (MS 0.35) were dissolv ⁇ ed in 5 ml of physiological sodium chloride solution and warmed to about 35°C whereafter 3 mg diazepam were added. After storing for a short time a clear solution was obtained which was filled into an ampule after filtration through a membrane filter (0.45 microns).
- dexamethasone and 100 mg hydroxyethyl- ⁇ -cyclodextrin were dissolved in 5 ml water, sterilized by filtration through a membrane filter (0.22 microns) and packed into an aerosol container allowing to dispense 0.1 ml per dose.
- ⁇ -cyclodextrin 453 dimethyl- ⁇ -cyclodextrin 200-207
- mice * a higher dose has not been tested. In mice the value was > 4000 mg/kg.
- the haemolytic effect of the methylether according to German Offenlegungsschrift 31 18 218 was compared to that of an ether used according to the invention.
- 100 ⁇ l of a physiological sodium chloride solution with a cyclodextrin content of 10% 800 ⁇ l of a buffer (400 mg MOPS, 36 mg Na 2 HP0 4 . 2 H 2 0, 1,6 g NaCl in 200 ml H 2 0) and 100 ⁇ l of a suspension of human red blood cells (three times washed with sodium chloride solution) were mixed for 30 minutes at 37°C. Thereafter the mixture was centrifuged and the optical density was determined at 540 nm.
Abstract
Novel pharmaceutical compositions comprise inclusion compounds of drugs, which are instable or only sparingly soluble in water, with partially etherified beta-cyclodextrin derivatives having hydroxyalkyl and optionally additional alkyl groups.
Description
-/ -
Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
The invention relates to pharmaceutical compositions con- taining drugs which are instable or only sparingly soluble in water, and methods for their preparation. The compo¬ sitions are characterized by increased water solubility and improved stability.
A large number of drugs is only poorly or sparingly soluble in water so that suitable application forms " like drop solutions or injection solutions are being prepared using other polar additives like propylene glycol etc. If the drug molecule has basic or acidic groups there exists the further possibility of increasing the water solubility by salt formation. As a rule this results in decreased efficacy or impaired chemical stability. Due to the shifted distribution equilibrium the drug may penetrate the lipophilic membrane only slowly corresponding to the concentration of the non-dissociated fraction while the ionic fraction _may be subject to a rapid hydrolytic decomposition.
Additional "water-like" solvents like low molecular poly- ethylene glycols or 1 ,2-propylene glycol are therefore used in the preparation of aqueous solutions of sparingly water-soluble drugs which glycols, however, cannot be considered pharmacologically inert, or the drug is solubi- lized using surfactants so that the drug molecules are occluded in micells. This solubilization has numerous
disadvantages: The surfactant molecules used have frequent¬ ly a strongly haemolytic effect and the drug needs to pass out of the micell by diffusion after the application. This results in a retard effect (compare B.W. Muller, Gelbe Reihe, Vol. X, pages 132ff (1983)).
Accordingly it may be stated that there exists no satis¬ factory and generally applicable method of solubilization.
For solid drugs it is also important to render the sparingly water-soluble drug water-soluble since a good solubility increases the bioavailability of the drug. It has been described that inclusion compounds, e.g. with μrea or complexes of polyvinyl pyrrolidone may improve the solubility of a compound but in aqueous solution they are not stable. Such inclusion compounds are therefore at' best suitable for solid application forms of drugs.
This is different when using -, a-, and γ-cyclodextrin which can bind a drug in its ring also in aqueous solution (W. Sanger, Angewandte Chemie , 343 (1980)). However, it is disadvantageous that the S-cyclodextrin itself is only poorly water-soluble (1.8 g/100 ml) so that the therapeuti- cally necessary drug concentrations are not achieved.
If a derivative is formed of the cyclodextrin its solubili¬ ty and therefore the amount of dissolved drug may be considerably increased. Thus, German Offenlegungsschrift 31 18 218 discloses a solubilization method using methylat- ed β-cyclodextrin as monomethyl derivative with 7 methyl groups and especially as dimethyl derivative with 14 methyl groups. With the 2,6-di-O-methyl derivative it is for instance possible to increase the water solublity of indometacin 20.4-fold and that of digitoxin 81.6-fold.
However, for therapeutical use the methyl derivatives of β-cyclodextrin show serious draw backs. Due to their increased lipophility they have a haemolytic effect and they further cause irritations of the mucosa and eyes. Their acute intravenous toxicity is still higher than the already considerable toxicity of the unsubstituted β-cyclo¬ dextrin. It is a further serious disadvantage for 'the practical "application that the solubility of the dimethyl β-cyclodextrin and its complexes suffers a steep decrease at higher temperatures so that crystalline dextrin precipi¬ tates upon heating. This phenomenon makes it very diffi¬ cult to sterilize the solutions at the usual temperatures of 100 to 121°C.
Quite surprisingly it has now been found that certain other β-cyclodextrin derivatives can form inclusion 'com¬ pounds which also considerably increase the water-solubili¬ ty of sparingly water-soluble and instable drugs without showing the advantages described above.
Subject of the invention are therefore novel pharmaceuti¬ cal compositions comprising inclusion compounds of only sparingly water-soluble and in water instable drugs with a partially etherified β-cyclodextrin of the formula
(β-CD*0R (I),
in which the residues R are hydroxyalkyl groups and part of the residues R may optionally be alkyl groups, the β-cyclodextrin ether having a water-solubility of more than 1.8 g in 100 ml water.
A partially etherified β-cyclodextrin of formula I is preferably used in which the residues R are hydroxyethyl, hydroxypropyl or dihydroxypropyl groups. Optionally part of the residues R may for instance be methyl or ethyl
- 4 -
groups; the use of partially • methylated β-cyclodextrin ethers with 7 to 14 methyl groups in the β-cyclodextrin molecule, as they are known from German Offenlegungs- schrift 31 18 218 do not come under the present invention. Partial ethers of β-cyclodextrin comprising only alkyl groups (methyl, ethyl) may be suitable in accordance with the invention if they have a low degree of substitution (as defined below) of 0.05 to 0.2.
β-cyclodextrin is a compound with ring structure consist¬ ing of 7 anhydro glucose units; it is also referred to as cycloheptaamylose. Each of the 7 glucose rings contains in 2-,3-, and 6-position three hydroxy groups which may be etherified. In the partially etherified β-cyclodextrin derivatives used according to the invention only part of these hydroxy groups is etherified with hydroxyalkyl groups and optionally further with alkyl groups. When etherifying with hydroxy alkyl groups -which can be carried out by reaction with the corresponding alkylene oxides, "the degree of substitution is stated as molar substitution (MS), viz. in mole alkylene oxide per anhydroglucose unit, compare US patent specification 34 59 731, column 4..In the hydroxyalkyl ethers of β-cyclodextrin used in accor¬ dance with the invention the molar substitution is between 0.05 and 10, preferably between 0.2 and 2. Particularly preferred is a molar substitution of about 0.25 to about 1.
The etherification with alkyl groups may be stated direct- ly as degree of substitution (DS) per glucose unit which - as stated above - is 3 for complete substitution. Partial¬ ly etherified β-cyclodextrins are used within the in¬ vention which comprise besides hydroxyalkyl groups also alkyl groups, especially "methyl or ethyl groups, up to a degree of substitution of 0.05 to 2.0, preferably 0.2 to 1.5. Most preferably the degree of substitution with alkyl groups is between about 0.5 and about 1.2.
The molar ratio of drug to β-cyσlodextrin ether is preferably about 1:6 to 4:1, especially about 1:2 to 1:1. As a rule it is preferred to use the complex forming agent in a molar excess.
Useful complex forming agents are especially the hydroxy- ethyl, hydroxypropyl and dihydroxypropyl ether, their corresponding mixed ethers, and further mixed ethers with methyl or ethyl groups, such as methyl-hydroxyethyl, methyl-hydroxypropyl, ethyl-hydroxyethyl and ethyl-hydroxy¬ propyl ether of β-cyclodextrin.
The preparation of the hydroxyalkyl ethers of β-cyclo¬ dextrin may be carried out using the method of US patent specification 34 59 731. Suitable preparation methods for β-cyclodextrin ethers may further be found in J. Szejtli et al., Starke 3_2., 165 (1980) und A.P. Croft and R.A. Bartsch, Tetrahedron 3_9_, 1417 (1983). Mixed ethers of β-cyclodextrin can be prepared by reacting β-cyσlodextrin in a basic liquid reaction medium comprising an akali metal hydroxide, water and optionally at least one organic solvent (e.g. dimethoxyethane or isopropanol) with at least two different hydroxyalkylating and optionally al- kylating etherifying agents (e.g. ethylene oxide, propy- lene oxide, methyl or ethyl chloride).
Drugs exhibiting a significantly increased water-solubili¬ ty and improved stability, respectively, after having been transferred into inclusion compounds with the above- en- tioned β-cyclodextrin ethers are those having the required shape and size, i.e. which fit into the cavity of the β-cyclodextrin ring system. This includes for instance non-steroid anti-rheumatic agents, steroids, cardiac glyco- sides and derivatives of benzodiazep'ine, beήzimidazole, piperidine, piperazine, imidazole or triazole.
- 6 -
Useful benzimidazole derivatives are thiabendazole, fuberi- dazole, oxibendazole, parbendazole, cambendazole, mebenda- zole, fenbendazole, flubendazole, albendazole, oxfenda- zole, nocodazole and astemisole. Suitable piperadine deri- vatives are fluspirilene, pimozide, penfluridole, loperamide, astemizole, ketanserine, levocabastine, cisa- pride, altanserine, and ritanserine. Suitable piperazine derivatives include lidoflazine, flunarizine, mianserine, oxatomide, mioflazine and cinnarizine. Examples of suitable imidazole derivatives are metronidazole, ornidazole, ipronidazole, tinidazole, isoconazole, nimora- zole, burimamide, metiamide, metomidate, enilconazole, etomidate, econazole, clotrimazole, carnidazole, cimetidine, docodazole, sulconazole, parconazole, orconazole, butocona- zole, triadiminole, tioconazole, valconazole, fluotrimazole, ketoconazole, oxiconazole, lombazole, bifonazole, oxmeti- dine, fenticonazole and tubulazole. As suitable triazole derivatives there may be mentioned virazole, itraconazole and terconazole.
Particularly valuable pharmaceutical compositions are ob¬ tained when converting etomidate, ketoconazole, tubulazole, itraconazole, levocabastine or flunarizine into a water-so¬ luble form using the complex forming agents of the invention. Such compositions are therefore a special subject of the present invention.
The invention is further directed to a method of preparing pharmaceutical compositions of sparingly water-soluble or water-instable drugs which is characterized by dissolving the β-cyclodextrin ether in water and adding thereto the selected drug as well as optionally drying the solution of the formed inclusion compound using methods known per se.
Formation of the solution may take place at temperatures between 15 and 35 C.
- 7 -
The drug is suitably added batchwise. The water may further comprise physiologically compatible compounds such as sodium chloride, potassium nitrate, glucose, mannitole, sorbitol, xylitol or buffers such as phosphate, acetate or citrate buffer.
Using β-cyclodextrin ethers in .accordance with the in¬ vention it is possible to prepare application forms of drugs for oral, parenteral or topical application, e.g. infusion and injection solutions, drop solutions (e.g. eye drops or nasal drops), sprays, aerosols, sirups, and medical baths.
The aqueous solutions may further comprise suitable physio- logically compatible preserving agents such as quarternary ammonium soaps or chlorbutanol.
For the preparation of solid formulations the solutions of the inclusion compounds are dried using conventional methods; thus the water may be evaporated in a rotation evaporator or by lyophilisation. The residue is pulverized and, optionally after addition of further inert ingre¬ dients, converted into uncoated or coated tablets, supposi¬ tories, capsules, creams or ointments.
The following examples serve to illustrate the invention which, however, is not restricted to the examples.
The phosphate buffer solution mentioned in the examples had a pH of 6.6 and the following composition:
KH2P04 68,05 g
NaOH 7,12 g
Aqua demin. ad. 5000,0 g
All percentages are percent by weight.
Example 1
Starting from a 7% master solution of hydroxyethyl β-cyclo¬ dextrin (MS 0.43) in phosphate buffer solution a dilution series was prepared so that the complex forming agent concentration was increased in steps of 1%. 3 ml of these solutions were pipetted into 5 ml snap-top-glasses contain¬ ing the drug to be tested. After shaking for 24 hours at
25°C the solution was filtered through a membrane filter (0.22 microns) and the dissolved drug content was determin¬ ed spectrophotometrically. Figures 1, 3 and 4 show the increase of the drug concentration in solution in relation to the concentration of the complex forming agent for indometacin (figure 1) , piroxicam (figure 3) and dia'zepam (figure 4) . The maximum drug concentration is limited by the saturation solubility of the cyclodextrin derivative in the buffer which in case of hydroxyethyl-β-cyclodextrin (MS 0.43) is reached at 7.2 g/100 ml.
When comparing for instance the results obtained with indometacin to those given in German Offenlegungsschrift 31 18 218 for 2,6-di-0-methyl-β-cyclodextrin (figure 2) it will be observed that the hydroxyethyl derivative has a significantly higher complex formation constant (compare the different slopes in figures 1 and 2) .
Example 2
A. The saturation solubility at 25°C of different drugs was determined using a 10% hydroxypro- pyl-β-cyclodextrin solution (MS 0.35) in phosphate buffer solution under the same conditions as in example 1. The saturation solubilities S.. in phosphate buffer solution and
S- in phosphate buffer solution and 10% added hydroxypropyl-β-cyσlodextrin are given in table 1.
Table 1
Drugs S-j (mg/ml) S2 (mg/ml) Ratio S1 :S_
Indometacine 0,19 5 , 72 30,1
Digitoxine 0,002 1 , 685 842,5
Progesterone 0,0071 7 , 69 1083,0
Dexamethasone 0,083 14 , 28 172,0
Hydrocortisone 0,36 21 , 58 59,9 Diazepame 0,032 0 , 94 29,4
B. The solubility of drugs in a 4% aqueous solution of hydroxypropyl-methyl-β-cyclodextrin (DS 0.96; MS 0.43) was determined in a similar manner. The results obtained are summarized in the following table 2 in which the ratio R of the saturation solubility in water or at the stated pH, re¬ spectively, with an without addition of β-cyclo¬ dextrin derivative is stated for each drug. The solutions prepared according to the invention were further found to be significantly more stable when compared with aqueous solutions.
- 10 -
Table 2
Drug R
Itraconazole at pH 5 96 at pH 2 , ■ 5 75
Flunarizine 18
Levocabastine at pH 9, .5 81 at pH 1 , ,4 8
Ketoconazole 85
Flubendazole 30
Tubulazole 43
Cisapride 3
Loperamide 62
Etomidate 8,5
Cinnarizine at pH 5 28 at pH 3 12
Example 3
In 10 ml phosphate buffer solution 0.7 g hydroxyethyl-β-cy¬ clodextrin (MS 0.43) were dissolved together with 0.04 g indometacin at 25 C until a clear solution was formed. This solution was filtered through a membrane filter (0.22 microns) and filled under laminar flow into a pre-steriliz- ed injection bottle which was stored at 21°C (B). In a parallel test a saturated indometacin solution in a phosphate buffer solution (0.21 mg/ml) was stored under the same conditions (A) . The drug concentrations determin¬ ed by high pressure liquid chromatography are given in table 3. The great improved stability of the composition according to the invention is apparent.
Table 3 •
Storing time Indometacin content (%) in weeks A B
0 100,1 99,7
2 91,2 99,9
4 79,1 98,1
6 69,8 98,6
8 64,8 98,4
Example 4 (Injectable formulation)
0.35 g hydroxypropyl-β-cyclodextrin (MS 0.35) were dissolv¬ ed in 5 ml of physiological sodium chloride solution and warmed to about 35°C whereafter 3 mg diazepam were added. After storing for a short time a clear solution was obtained which was filled into an ampule after filtration through a membrane filter (0.45 microns).
Example 5 (Tablet)
In 100 ml water 7 g hydroxyethyl-β-cyclodextrin (MS 0.43) and 0.5 g medroxyprogesterone acetate were dissolved. The water was then evaporated in a rotation evaporator. The residue (75 mg) was powdered and. after addition of 366 mg calcium hydrogen phosphate.2H.-0, 60 mg corn starch, 120 mg cellulose powder (microcrystalline) , 4.2 mg highly dispers- ed silica (AEROSIL 200) and 4.8 mg magnesium stearate tablets with a weight of 630.0 mg and comprising 5 mg drug per unit dose were made. The dissolution rate of the medroxyprogesterone acetate from this formulation is 21 times higher when compared to a tablet comprising the same inert ingredients without addition of the β-cyclodextrin ether.
Example 6
5 g hydroxyethyl-β-cyclodextrin (MS 0,43) and 14 mg vitamin A-acetate were dissolved with stirring in 100 ml water or sugar solution (5% aqueous solution) within 2.5 hours under a nitrogen atmosphere. After filtration through a membrane filter (0.45 microns) the solution was filled into ampules and sterilized or filled into dropper bottles with addition of 0.4% chlor butanol as preserving agent.
Example 7
5 or 7.5 g hydroxyethyl β-cyclodextrin (MS 0.43) and 0.5 or 0.75 g Lidocaine were dissolved in 100 ml of physiologi¬ cal sodium chloride solution at 30°C (B). Injection solutions, eye droplets and solutions for topical use were prepared therefrom as described in example 6. When compar¬ ing the anaethesic effect of these solutions in animal tests with an aqueous lidocain HC1 solution (A) one observes an extension of the duration of the effect by 300%. Test: rats, injection of 0.1 ml into the tail root in the vicinity of the right or left nerve fillaments and electrical irritation. The test results are summarized in table 4.
Table 4
Drug concentration Duration of effect (min) Extension (%) A B (%)
0,5 56 163 291
0,75 118 390 330
Example 8
6 mg dexamethasone and 100 mg hydroxyethyl-β-cyclodextrin (MS 0.43) were dissolved in 5 ml water, sterilized by filtration through a membrane filter (0.22 microns) and packed into an aerosol container allowing to dispense 0.1 ml per dose.
Example 9
The acute intravenous toxicity of some β-cyclodextrins was tested on rats with the following results. It was sur¬ prisingly found that the toxicity of the derivatives used according to the invention is lower by an entire order of magnitude.
Table 5
LD50 in rats (i.v.) in mg/kg bodyweight
β-cyclodextrin 453 dimethyl-β-cyclodextrin 200-207
(DS 2.0) hydroxypropyl-methyl- β-cyclodextrin > 2000*
(DS 0.96; MS 0.43)
* a higher dose has not been tested. In mice the value was > 4000 mg/kg.
The haemolytic effect of the methylether according to German Offenlegungsschrift 31 18 218 was compared to that of an ether used according to the invention. To this end 100 μl of a physiological sodium chloride solution with a cyclodextrin content of 10%, 800 μl of a buffer (400 mg MOPS, 36 mg Na2HP04 . 2 H20, 1,6 g NaCl in 200 ml H20) and 100 μl of a suspension of human red blood cells (three times washed with sodium chloride solution) were mixed for 30 minutes at 37°C. Thereafter the mixture was centrifuged and the optical density was determined at 540 nm.
Controls: a) 100 μl sodium chloride solution + buffer -*■ 0% haemo¬ lysis b) 900 μl water →- 100% haemolysis
The results obtained are summarized in the following table 6 in which the concentrations are stated at which 50% and 100% haemolysis occurred.
- 15 -
Table 6
Substance C50% C100%
Dimethyl-β-CD 0,33% 0,5%
(DS 2.0)
Methyl-β-CD 0,53 0,8%
(DS 1.79)
Hydroxypropyl- methyl-β-CD 1,5% 4 %
(DS 0.96; MS 0. .43%)
The results show that the haemolytic effect of the hydroxypro pylmethyl ether is about 5 to 8 times weaker than that of th dimethyl ether according to the prior art. Animal tests hav further shown that the hydroxyalkyl ethers do not caus irritation of the ucosa and eyes in contrast to the methy ethers.
Claims
1. Pharmaceutical composition comprising an inclusio compound of drugs which are instable or only sparingly solubl in water with a partially etherified β-cyclodextrin of th formula
in which the residues R are hydroxyalkyl groups and in whic part of the residues R may optionally be alkyl groups, th β-cyclodextrin ether having a water solubility of more tha 1.8 g in 100 ml water.
2. Composition according to claim 1, characterized i that it comprises a partially etherified β-cyclodextrin o formula I, in which the residues R are hydroxyethyl, hydrox propyl or dihydroxypropyl groups and in which part of t residues R may optionally be methyl or ethyl groups
3. Composition according to claims 1 or 2, characteriz in that they comprise a partially etherified β-cyclodextrin formula I with a molar substitution by hydroxyalkyl groups 0.05 to 10 and a degree of substitution by alkyl groups 0.05 to 2.0.
4. Composition according to anyone of the claims 1 to characterized in that it comprises the drug and the β-cyσl dextrin ether in a molar ratio of 1:6 to 4:1.
5. Composition acσording to anyone of σlaims 1 to characterized in that it comprises as drug a non-steri anti-rheumatic agent, a steroid, a cardiaσ glycoside derivatives of benzodiazepine, benzimidazole, piperidin piperazine, imidazole or triazole.
6. Composition aσσording to anyone of σlaims 1 to 5 σharaσterized in that it comprises as drug etomidate
7. Composition according to anyone of claims 1 to 5 charaσterized in that it σomprises as drug ketoσonazole
8. Composition aσσording to anyone of σlaims 1 to 5 σharaσterized in that it comprises as drug itraconazole
9. Composition acσording to anyone of σlaims 1 to 5 σharaσterized in that it σomprises as drug levoσabastine
10. Composition aσσording to anyone of claims 1 to 5 charaσterized in that it σomprises as drug flunarizine
11. Composition aσσording to anyone of σlaims '1 to 5 σharaσterized in that it σomprises as drug tubulazole
12. A method of preparing a phar aσeutiσal σo positio aσσording to anyone of σlaims 1 to 11, σharaσterized in tha the β-σyσlodextrin ether is dissolved in water and that th seleσted drug is added whereafter the solution -of th inσlusion σompound thus obtained is optionally dried usin methods known per se.
13. The method of σlaim 12, σharaσterized in that th residue obtained after removal of the solvent is pulverize and, optionally after addition of further inert ingredients transferred into a solid appliσation form.
14. The method of σlaims 12 or 13, σharaσterized in tha further physiologically aσceptable substances are added to th water.
15. The method of σlaim 14 , σharaσterized in that sodi σhloride,' gluσose, mannitol, sorbitol, xylitol or a phospha or σitrate buffer are added to the water.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
HU85795D HU200943B (en) | 1983-12-21 | 1984-12-20 | Process for producing pharmaceutical compositions comprising active ingredients which are instable or badly soluble in water |
NO853070A NO171888C (en) | 1983-12-21 | 1985-08-02 | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL PREPARATION CONTAINING MEDICINAL SUBSTANCES WHICH ARE SOLELY SOLUBLE OR USTABILE IN WATER |
DK198503595A DK175288B1 (en) | 1983-12-21 | 1985-08-07 | Pharmaceutical agents containing drugs which are unstable or sparingly soluble in water, and methods for their preparation |
FI853198A FI86140C (en) | 1983-12-21 | 1985-08-20 | Process for the preparation of a pharmaceutical preparation containing a water-insoluble or water-unstable drug |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19833346123 DE3346123A1 (en) | 1983-12-21 | 1983-12-21 | PHARMACEUTICAL PREPARATIONS OF SUBSTANCES MEDICAL OR UNSTABLE IN WATER AND METHOD FOR THE PRODUCTION THEREOF |
DEP3346123.6 | 1983-12-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1985002767A1 true WO1985002767A1 (en) | 1985-07-04 |
Family
ID=6217510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP1984/000417 WO1985002767A1 (en) | 1983-12-21 | 1984-12-20 | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0149197B2 (en) |
JP (1) | JPS61500788A (en) |
AT (1) | ATE51145T1 (en) |
AU (1) | AU565966B2 (en) |
CA (1) | CA1222697A (en) |
CY (1) | CY1689A (en) |
DE (2) | DE3346123A1 (en) |
DK (1) | DK175288B1 (en) |
FI (1) | FI86140C (en) |
HK (1) | HK131293A (en) |
HU (1) | HU200943B (en) |
LU (1) | LU90283I2 (en) |
NL (1) | NL980009I1 (en) |
NO (1) | NO2000007I1 (en) |
SG (1) | SG24893G (en) |
WO (1) | WO1985002767A1 (en) |
ZA (1) | ZA8410042B (en) |
Cited By (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3712246A1 (en) * | 1986-04-16 | 1987-10-29 | American Maize Prod Co | METHOD FOR PRODUCING MODIFIED CYCLODEXTRINE |
EP0288019A1 (en) * | 1987-04-24 | 1988-10-26 | Bononi, & C. Gruppo di Ricerca Srl | Beta-cyclodextrin complexes having anti-mycotic activity |
GB2211737A (en) * | 1987-12-22 | 1989-07-12 | Glaxo Group Ltd | Aqueous formulations of piperidinylcyclopentylheptenoic acid derivatives |
WO1989006536A1 (en) * | 1988-01-19 | 1989-07-27 | Moses Judah Folkman | Growth inhibiting agent and the use thereof |
US4877774A (en) * | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
EP0346006A1 (en) * | 1988-06-09 | 1989-12-13 | Reckitt And Colman Products Limited | Pharmaceutical compositions containing ibuprofen-cyclodextrin complexes |
WO1990001320A1 (en) * | 1988-08-15 | 1990-02-22 | American Maize-Products Company | Water soluble branched beta cyclodextrin steroid complex |
EP0396184A2 (en) * | 1989-05-03 | 1990-11-07 | Janssen Pharmaceutica N.V. | Use of ketoconazole and a retinoid for the treatment of acne vulgaris |
US4983586A (en) * | 1987-12-30 | 1991-01-08 | University Of Florida | Pharmaceutical formulations for parenteral use |
US5017566A (en) * | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
US5019562A (en) * | 1988-01-19 | 1991-05-28 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Growth inhibiting agent and the use thereof |
WO1991011200A1 (en) * | 1990-01-29 | 1991-08-08 | Janssen Pharmaceutica N.V. | Improved cyclodextrin based erythropoietin formulation |
EP0449722A1 (en) * | 1990-03-27 | 1991-10-02 | Roussel-Uclaf | New complexes of tiaprofenic acid or its insoluble or partially soluble esters with cyclodextrines or their derivates |
WO1992004888A1 (en) * | 1990-09-20 | 1992-04-02 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Preparation of lipophile: hydroxypropyl cyclodextrin complexes by a method using co-solubilizers |
AU626538B2 (en) * | 1988-01-19 | 1992-08-06 | Moses Judah Folkman | Growth inhibiting agent and the use thereof |
EP0538011A1 (en) * | 1991-10-16 | 1993-04-21 | Schering Corporation | Lipophilic oligosaccharide antibiotic salt compositions |
EP0539938A1 (en) | 1991-10-30 | 1993-05-05 | Schering Corporation | Tri-substituted tetrahydrofuran antifungals |
US5221695A (en) * | 1987-12-22 | 1993-06-22 | Glaxo Group Limited | Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin |
US5229370A (en) * | 1988-08-15 | 1993-07-20 | Ammeraal Robert N | Water soluble branched beta cyclodextrin steroid complex |
US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
US5332582A (en) * | 1990-06-12 | 1994-07-26 | Insite Vision Incorporated | Stabilization of aminosteroids for topical ophthalmic and other applications |
WO1994020091A1 (en) * | 1993-03-05 | 1994-09-15 | Hexal Pharma Gmbh | Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation |
WO1994022455A1 (en) * | 1993-03-31 | 1994-10-13 | The Trustees Of The University Of Pennsylvania | Methods of affecting the growth of living tissue in mammals and compounds and compositions therefor |
WO1995005198A1 (en) * | 1993-08-17 | 1995-02-23 | Finn Molke Borgbjerg | Localanaesthetic preparation |
US5441944A (en) * | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
US5446030A (en) * | 1991-09-19 | 1995-08-29 | Weisz; Paul B. | Prevention of hemolysis |
US5447920A (en) * | 1988-10-28 | 1995-09-05 | Shiseido Company Ltd. | Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin |
WO1995032737A1 (en) * | 1994-05-27 | 1995-12-07 | Farmarc Nederland Bv | Pharmaceutical composition |
US5494901A (en) * | 1993-01-05 | 1996-02-27 | Javitt; Jonathan C. | Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent |
US5624940A (en) * | 1993-12-14 | 1997-04-29 | Eli Lilly And Company | Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof |
US5637575A (en) * | 1988-01-19 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting restenosis |
US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
US5658894A (en) * | 1989-04-23 | 1997-08-19 | The Trustees Of The University Of Pennsylvania | Compositions for inhibiting restenosis |
US5670530A (en) * | 1992-10-26 | 1997-09-23 | Fuji Photo Film Co., Ltd. | Anti-cancer composition comprising rhodacyanine compound and cyclodextrin |
US5730969A (en) * | 1988-10-05 | 1998-03-24 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5760015A (en) * | 1988-01-19 | 1998-06-02 | The Trustees Of The University Of Pennsylvania | Cyclodextrin compounds and methods of making and use thereof |
EP1029872A1 (en) * | 1997-11-07 | 2000-08-23 | Daiichi Pharmaceutical Co., Ltd. | Piperazine-cyclodextrin complexes |
WO2000056336A2 (en) * | 1999-03-18 | 2000-09-28 | Knoll Gmbh | Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin |
WO2001001955A1 (en) * | 1999-07-02 | 2001-01-11 | Janssen Pharmaceutica N.V. | Nasal formulation of an antifungal |
WO2001014291A1 (en) * | 1999-08-24 | 2001-03-01 | Astrazeneca Ab | Use of cyclodextrin for protective storage of chemical compound libraries |
US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
US6485743B1 (en) | 1997-12-31 | 2002-11-26 | Choongwae Pharma Corporation | Method and composition of an oral preparation of itraconazole |
US6566504B2 (en) | 1996-04-19 | 2003-05-20 | Alpha Therapeutic Corporation | Process for viral inactivation of lyophilized blood proteins |
WO2003075904A2 (en) * | 2002-03-07 | 2003-09-18 | Wrair | Cyclodextrin complexed artemisinins |
US6632803B1 (en) | 1997-06-21 | 2003-10-14 | Pfizer Inc | Pharmaceutical formulations containing voriconazole |
WO2004000344A1 (en) * | 2002-06-24 | 2003-12-31 | Merck Patent Gmbh | Aqueous preparation containing oligopeptides and etherified cyclodextrin |
US6818662B2 (en) | 2002-05-28 | 2004-11-16 | Taisho Pharmaceutical Co., Ltd. | Pharmaceutical composition |
BG64434B1 (en) * | 1997-03-26 | 2005-02-28 | Janssen Pharmaceutica Nv | Pellets containing core enveloped by intraconazol and polymer |
US6962944B2 (en) | 2001-07-31 | 2005-11-08 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
US6989381B2 (en) | 2000-08-22 | 2006-01-24 | Pharmacia Corporation | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading |
EP1637167A2 (en) * | 2004-09-16 | 2006-03-22 | Altergon S.A. | New injectable formulations containing progesterone |
US7074824B2 (en) | 2001-07-31 | 2006-07-11 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
WO2006137433A1 (en) * | 2005-06-21 | 2006-12-28 | Wakamoto Pharmaceutical Co., Ltd. | Aqueous preparation having levocabastine solubilized therein |
CN1294912C (en) * | 2004-03-01 | 2007-01-17 | 上海医药工业研究院 | Itraconazole hydrochloride composition and freeze-dried powder injection thereof |
WO2007038282A3 (en) * | 2005-09-26 | 2007-08-23 | B B Scient L L C | Stabilization of clostridium botulinum neurotoxin complex |
US7348317B2 (en) | 2001-12-24 | 2008-03-25 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
WO2009107877A1 (en) * | 2008-02-28 | 2009-09-03 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
CN102499909A (en) * | 2011-12-27 | 2012-06-20 | 哈尔滨三联药业有限公司 | Itraconazole dispersible tablets and preparation method thereof |
US8641948B2 (en) | 2006-08-16 | 2014-02-04 | Novartis Ag | Method of making solid dispersions of highly crystalline therapeutic compounds |
US8664252B2 (en) | 2008-11-25 | 2014-03-04 | Boehringer Ingelheim Vetmedica Gmbh | Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy |
US8846679B2 (en) | 2004-03-08 | 2014-09-30 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical composition comprising pimobendan |
EP2789349A1 (en) | 2006-11-07 | 2014-10-15 | Boehringer Ingelheim Vetmedica GmbH | Liquid preparation comprising pimobendan |
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
US9066940B2 (en) | 2009-02-06 | 2015-06-30 | Telormedix, Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
KR20150129697A (en) * | 2013-03-13 | 2015-11-20 | 시애틀 지네틱스, 인크. | Cyclodextrin and antibody-drug conjugate formulations |
US9463199B2 (en) | 2004-03-25 | 2016-10-11 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
US10071162B2 (en) | 2013-07-19 | 2018-09-11 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
US10172804B2 (en) | 2013-12-04 | 2019-01-08 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical compositions of pimobendan |
US10398705B2 (en) | 2012-03-15 | 2019-09-03 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
WO2020002851A1 (en) * | 2018-06-29 | 2020-01-02 | Roquette Freres | NOVEL HYDROXYPROPYL-β-CYCLODEXTRIN AND PROCESS FOR THE PRODUCTION THEREOF |
FR3083234A1 (en) * | 2018-06-29 | 2020-01-03 | Roquette Freres | NOVEL HYDROXYPROPYL-BETA-CYCLODEXTRINS AND PROCESSES FOR THEIR PREPARATION |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
CN114195733A (en) * | 2022-01-07 | 2022-03-18 | 华东理工大学 | Method for inhibiting isomerization of probenazole |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0819004B2 (en) * | 1986-12-26 | 1996-02-28 | 日清製粉株式会社 | Sustained-release pharmaceutical preparation |
NZ224497A (en) * | 1987-05-18 | 1990-04-26 | Janssen Pharmaceutica Nv | Pharmaceutical composition comprising flunarizine |
JP2577049B2 (en) * | 1987-06-04 | 1997-01-29 | 三共株式会社 | Cyclosporine preparation |
NZ225045A (en) * | 1987-07-01 | 1990-06-26 | Janssen Pharmaceutica Nv | Antiviral pharmaceutical compositions containing cyclodextrin and an antiviral agent |
ZA884592B (en) * | 1987-08-31 | 1989-03-29 | Warner Lambert Co | Cyclodextrin complexes of bis-biguanido hexane compounds |
ATE74003T1 (en) * | 1988-01-14 | 1992-04-15 | Akzo Nv | AQUEOUS PHARMACEUTICAL PREPARATION. |
DE3809808A1 (en) * | 1988-03-23 | 1989-10-05 | Hexal Pharma Gmbh & Co Kg | SOLIDS, ESPECIALLY FESTORAL AND RECTAL, ETOFENAMATE-CONTAINING MEDICINAL PRODUCTS |
US5236944A (en) * | 1988-03-28 | 1993-08-17 | Janssen Pharmaceutica N.V. | Compounds, compositions and anti-neoplastic methods |
DE3815902A1 (en) * | 1988-05-10 | 1989-11-23 | Schwarz Pharma Gmbh | Inclusion compounds of 1-(4-(2-(5-chloro-2-methoxybenzamido)ethyl)phenylsulphonyl)-3-cyclohex ylurea with alpha -, beta - and gamma -cyclodextrins, a pharmaceutical product containing these in each case, and process for the production thereof |
NL8801670A (en) | 1988-07-01 | 1990-02-01 | Walter Adrianus Josephus Johan | PHARMACEUTICAL PREPARATION. |
MY106598A (en) * | 1988-08-31 | 1995-06-30 | Australian Commercial Res & Development Ltd | Compositions and methods for drug delivery and chromatography. |
JP2929108B2 (en) * | 1988-10-28 | 1999-08-03 | 株式会社資生堂 | Cosmetics and powder cosmetics |
IT1227626B (en) * | 1988-11-28 | 1991-04-23 | Vectorpharma Int | SUPPORTED DRUGS WITH INCREASED DISSOLUTION SPEED AND PROCEDURE FOR THEIR PREPARATION |
JPH0737390B2 (en) * | 1989-08-29 | 1995-04-26 | 久光製薬株式会社 | Ointment composition |
WO1991004026A1 (en) * | 1989-09-14 | 1991-04-04 | Australian Commercial Research & Development Limited | Drug delivery compositions |
US5053240A (en) * | 1989-10-24 | 1991-10-01 | Kalamazoo Holdings, Inc. | Norbixin adducts with water-soluble or water-dispersible proteins or branched-chain or cyclic polysaccharides |
WO1991013100A1 (en) * | 1990-03-02 | 1991-09-05 | Australian Commercial Research & Development Limited | Cyclodextrin compositions and methods for pharmaceutical and industrial applications |
JP2867162B2 (en) * | 1990-03-31 | 1999-03-08 | 株式会社資生堂 | Peel-off type pack cosmetics |
LU87843A1 (en) * | 1990-11-15 | 1992-08-25 | Cird Galderma | AQUEOUS GEL BASED ON RETINOIC ACID AND HYDROXYPROPYL-BETA-CYCLODEXTRIN AND ITS USE IN HUMAN MEDICINE AND COSMETICS |
JPH04351603A (en) * | 1991-05-29 | 1992-12-07 | Toppan Printing Co Ltd | Cyclodextrin derivative |
EP0519428B1 (en) * | 1991-06-21 | 2000-09-20 | Takeda Chemical Industries, Ltd. | Cyclodextrin compositions with fumagillol derivates |
US5254541A (en) * | 1991-11-15 | 1993-10-19 | Merck Frosst Canada, Inc. | (Quinolin-2-ylmethoxy)indole/cyclodextrin complex |
DE4207922A1 (en) * | 1992-03-13 | 1993-09-23 | Pharmatech Gmbh | New water-soluble inclusion complexes contg randomly substd. methyl-beta-cyclodextrin - for admin. of substances which are only sparingly soluble in water |
US5324718A (en) * | 1992-07-14 | 1994-06-28 | Thorsteinn Loftsson | Cyclodextrin/drug complexation |
US5472954A (en) * | 1992-07-14 | 1995-12-05 | Cyclops H.F. | Cyclodextrin complexation |
DE4227569C1 (en) * | 1992-08-20 | 1994-06-09 | Inst Chemo Biosensorik | Enzymatic determn. of inorganic phosphate - using combination of di:saccharide phosphorylase, phosphatase or maltose synthase, and glucose oxido-reductase |
TW251236B (en) * | 1992-09-10 | 1995-07-11 | Ciba Vision Ag | |
PH31594A (en) * | 1993-09-30 | 1998-11-03 | Janssen Pharmaceutica Nv | Oral formulations on an antifungal. |
AU1716995A (en) * | 1994-03-18 | 1995-10-09 | Ciba-Geigy Ag | Aqueous solution of levocabastine for ophthalmic use |
DE4414138A1 (en) * | 1994-04-22 | 1995-10-26 | Consortium Elektrochem Ind | Acylated gamma cyclodextrins |
FR2726765B1 (en) * | 1994-11-14 | 1996-12-20 | Cis Bio Int | RADIOPHARMACEUTICAL COMPOSITIONS COMPRISING A COMPLEX INCLUDING A CYCLODEXTRIN AND A RADIOHALOGEN FATTY ACID |
US5576311A (en) * | 1994-11-30 | 1996-11-19 | Pharmos Corporation | Cyclodextrins as suspending agents for pharmaceutical suspensions |
FR2735136B1 (en) * | 1995-06-08 | 1997-08-14 | Roquette Freres | PULVERULENT COMPOSITION OF HYDROXYPROPYL-BETACYCLODEXTRIN AND ITS PREPARATION PROCESS. |
JP2920611B2 (en) * | 1995-12-11 | 1999-07-19 | 株式会社シーエーシー | Topical treatment for dermatitis |
GB9605705D0 (en) | 1996-03-19 | 1996-05-22 | Pfizer Ltd | Therapeutic agents |
SE9601556D0 (en) * | 1996-04-24 | 1996-04-24 | Astra Ab | New pharmaceutical formulation of a thrombin inhibitor for parenteral use |
DK0877600T3 (en) * | 1996-08-09 | 2004-02-02 | Alcon Mfg Ltd | Preservation system for pharmaceutical preparations containing cyclodextrin |
US5942501A (en) * | 1996-08-16 | 1999-08-24 | Collaborative Laboratories, Inc. | Cyclodextrin derivative complex |
EP0838225A3 (en) * | 1996-10-25 | 1999-03-24 | Hiji, Yasutake | Aqueous local anesthetic solution |
US6683100B2 (en) | 1999-01-19 | 2004-01-27 | Novartis Ag | Organic compounds |
US6194181B1 (en) | 1998-02-19 | 2001-02-27 | Novartis Ag | Fermentative preparation process for and crystal forms of cytostatics |
DE19848303A1 (en) * | 1998-10-14 | 2000-04-20 | Schering Ag | Stable combination of 14,17-over-bridged steroid gestagen and cyclodextrin compound, useful for treating climacteric disorders or for contraception |
EP1278549B1 (en) | 2000-05-02 | 2008-12-10 | Theravance, Inc. | Composition containing a cyclodextrin and a glycopeptide antibiotic |
US6982256B2 (en) | 2001-09-07 | 2006-01-03 | Boehringer Ingelheim Pharma Kg | Tolerance of 4-(4-(2-pyrrolylcarbonyl)-1-piperazinyl)-3-trifluoromethyl-benzoylguanidine in intravenous administration |
CA2463687A1 (en) | 2001-10-18 | 2003-04-24 | Decode Genetics Ehf | Cyclodextrin complexes |
GB0127677D0 (en) * | 2001-11-19 | 2002-01-09 | Vianex S A | Inclusion complex |
JP2005521690A (en) | 2002-02-22 | 2005-07-21 | ファルマシア・コーポレーション | Ophthalmic preparations containing rubber |
ATE476177T1 (en) | 2003-03-28 | 2010-08-15 | Ares Trading Sa | ORAL PREPARATIONS CONTAINING CLADRIBINE |
MXPA05010330A (en) | 2003-03-28 | 2006-05-31 | Ivax Corp | Cladribine formulations for improved oral and transmucosal delivery. |
UA81305C2 (en) | 2003-07-02 | 2007-12-25 | Ares Trading Sa | Formulation of cladribine (variants), cladribine-cyclodextrin complex, use of cladribine-cyclodextrin complex, mixture |
KR20090065537A (en) * | 2006-10-20 | 2009-06-22 | 이코스 코포레이션 | Compositions of chk1 inhibitors and cyclodextrin |
BRPI0719096A2 (en) * | 2006-11-21 | 2013-12-03 | Novartis Ag | STABLE PARENTAL FORMULATION CONTAINING AN RSV INHIBITOR OF A BENZODIAZEPINA STRUCTURE |
KR101383941B1 (en) * | 2012-03-09 | 2014-04-10 | 동아에스티 주식회사 | Stable pharmaceutical composition containing piroxicam or its pharmaceutical acceptable salt and hyaluronic acid and its pharmaceutical acceptable salt and their manufacturing method thereof |
ES2600628T3 (en) * | 2012-06-28 | 2017-02-10 | Johnson & Johnson Consumer Inc. | Racecadotril liquid composition |
ES2750246T3 (en) * | 2013-10-08 | 2020-03-25 | Innopharma Inc | Aprepitant oral liquid formulations |
KR20200020899A (en) * | 2017-06-30 | 2020-02-26 | 셀진 코포레이션 | 2- (4-chlorophenyl) -N-((2- (2,6-dioxopiperidin-3-yl) -1-oxoisoindolin-5-yl) methyl) -2,2-difluoro Compositions and Methods of Use of Acetamide |
US10716774B1 (en) | 2018-01-05 | 2020-07-21 | Yale Pharmaceuticals LLC | Pharmaceutical compositions containing isotretinoin with improved dissolution profile and enhanced stability |
CA3114021A1 (en) | 2018-10-29 | 2021-05-07 | Cyclo Therapeutics, Inc. | Methods for treating alzheimer's disease |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1548917A (en) * | 1966-12-16 | 1968-12-06 | ||
US3453259A (en) * | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
FR2484252A1 (en) * | 1980-05-09 | 1981-12-18 | Chinoin Gyogyszer Es Vegyeszet | PROCESS FOR THE PREPARATION OF AQUEOUS SOLUTIONS OF BIOLOGICALLY ACTIVE ORGANIC COMPOUNDS INSOLUBLE OR LITTLE SOLUBLE IN WATER |
WO1982000251A1 (en) * | 1980-07-21 | 1982-02-04 | Commerce Us | Water soluble form of retinoids |
-
1983
- 1983-12-21 DE DE19833346123 patent/DE3346123A1/en not_active Withdrawn
-
1984
- 1984-12-20 WO PCT/EP1984/000417 patent/WO1985002767A1/en active IP Right Grant
- 1984-12-20 AU AU38352/85A patent/AU565966B2/en not_active Expired
- 1984-12-20 JP JP60500307A patent/JPS61500788A/en active Granted
- 1984-12-20 DE DE8484115965T patent/DE3481680D1/en not_active Expired - Lifetime
- 1984-12-20 EP EP84115965A patent/EP0149197B2/en not_active Expired - Lifetime
- 1984-12-20 AT AT84115965T patent/ATE51145T1/en active
- 1984-12-20 HU HU85795D patent/HU200943B/en unknown
- 1984-12-21 CA CA000470876A patent/CA1222697A/en not_active Expired
- 1984-12-21 ZA ZA8410042A patent/ZA8410042B/en unknown
-
1985
- 1985-08-07 DK DK198503595A patent/DK175288B1/en active
- 1985-08-20 FI FI853198A patent/FI86140C/en active IP Right Grant
-
1993
- 1993-03-04 SG SG248/93A patent/SG24893G/en unknown
- 1993-11-25 HK HK1312/93A patent/HK131293A/en not_active IP Right Cessation
-
1994
- 1994-01-14 CY CY168994A patent/CY1689A/en unknown
-
1998
- 1998-02-26 NL NL980009C patent/NL980009I1/en unknown
- 1998-09-02 LU LU90283C patent/LU90283I2/en unknown
-
2000
- 2000-08-21 NO NO2000007C patent/NO2000007I1/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1548917A (en) * | 1966-12-16 | 1968-12-06 | ||
US3453259A (en) * | 1967-03-22 | 1969-07-01 | Corn Products Co | Cyclodextrin polyol ethers and their oxidation products |
FR2484252A1 (en) * | 1980-05-09 | 1981-12-18 | Chinoin Gyogyszer Es Vegyeszet | PROCESS FOR THE PREPARATION OF AQUEOUS SOLUTIONS OF BIOLOGICALLY ACTIVE ORGANIC COMPOUNDS INSOLUBLE OR LITTLE SOLUBLE IN WATER |
WO1982000251A1 (en) * | 1980-07-21 | 1982-02-04 | Commerce Us | Water soluble form of retinoids |
Cited By (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4920214A (en) * | 1986-04-16 | 1990-04-24 | American Maize-Products Company | Process for producing modified cyclodextrins |
DE3712246A1 (en) * | 1986-04-16 | 1987-10-29 | American Maize Prod Co | METHOD FOR PRODUCING MODIFIED CYCLODEXTRINE |
US5422347A (en) * | 1987-04-24 | 1995-06-06 | Bononi & C. Gruppo Di Ricerca S.R.L. | β-cyclodextrin complexes of miconazole and econazole |
EP0288019A1 (en) * | 1987-04-24 | 1988-10-26 | Bononi, & C. Gruppo di Ricerca Srl | Beta-cyclodextrin complexes having anti-mycotic activity |
US4877774A (en) * | 1987-09-09 | 1989-10-31 | The United States Of America As Represented By The Department Of Health And Human Services | Administration of steroid hormones |
US5256652A (en) * | 1987-11-12 | 1993-10-26 | Pharmedic Co. | Topical compositions and methods for treatment of male impotence |
GB2211737A (en) * | 1987-12-22 | 1989-07-12 | Glaxo Group Ltd | Aqueous formulations of piperidinylcyclopentylheptenoic acid derivatives |
GB2211737B (en) * | 1987-12-22 | 1991-12-11 | Glaxo Group Ltd | Aqueous formulations containing a piperidinylcyclopentylheptenoic acid derivative |
US5221695A (en) * | 1987-12-22 | 1993-06-22 | Glaxo Group Limited | Aqueous formulation containing a piperidinylcyclopentylheptenoic acid derivative and beta-cyclodextrin |
US5024998A (en) * | 1987-12-30 | 1991-06-18 | University Of Florida | Pharmaceutical formulations for parenteral use |
US4983586A (en) * | 1987-12-30 | 1991-01-08 | University Of Florida | Pharmaceutical formulations for parenteral use |
US5002935A (en) * | 1987-12-30 | 1991-03-26 | University Of Florida | Improvements in redox systems for brain-targeted drug delivery |
US5017566A (en) * | 1987-12-30 | 1991-05-21 | University Of Florida | Redox systems for brain-targeted drug delivery |
US5019562A (en) * | 1988-01-19 | 1991-05-28 | The Trustees Of The University Of Pennsylvania/Childrens Hospital Corporation | Growth inhibiting agent and the use thereof |
US5637575A (en) * | 1988-01-19 | 1997-06-10 | The Trustees Of The University Of Pennsylvania | Methods of inhibiting restenosis |
US5760015A (en) * | 1988-01-19 | 1998-06-02 | The Trustees Of The University Of Pennsylvania | Cyclodextrin compounds and methods of making and use thereof |
AU626538B2 (en) * | 1988-01-19 | 1992-08-06 | Moses Judah Folkman | Growth inhibiting agent and the use thereof |
GR1000597B (en) * | 1988-01-19 | 1992-08-26 | Judah Moses Folkman | Growth suspension agent and use thereof |
WO1989006536A1 (en) * | 1988-01-19 | 1989-07-27 | Moses Judah Folkman | Growth inhibiting agent and the use thereof |
EP0346006A1 (en) * | 1988-06-09 | 1989-12-13 | Reckitt And Colman Products Limited | Pharmaceutical compositions containing ibuprofen-cyclodextrin complexes |
US5376641A (en) * | 1988-08-15 | 1994-12-27 | American Maize Technology, Inc. | Method for making a steroid water soluble |
WO1990001320A1 (en) * | 1988-08-15 | 1990-02-22 | American Maize-Products Company | Water soluble branched beta cyclodextrin steroid complex |
US5229370A (en) * | 1988-08-15 | 1993-07-20 | Ammeraal Robert N | Water soluble branched beta cyclodextrin steroid complex |
US5730969A (en) * | 1988-10-05 | 1998-03-24 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5997856A (en) * | 1988-10-05 | 1999-12-07 | Chiron Corporation | Method and compositions for solubilization and stabilization of polypeptides, especially proteins |
US5447920A (en) * | 1988-10-28 | 1995-09-05 | Shiseido Company Ltd. | Cosmetic composition containing inclusion product with hydroxyalkylated cyclodextrin |
US5902799A (en) * | 1989-04-23 | 1999-05-11 | The Trustees Of The University Of Pennsylvania | Methods of modulating tissue growth and regeneration |
US5935940A (en) * | 1989-04-23 | 1999-08-10 | Trustees Of The University Of Pennsylvania | Compositions and methods for modulating growth of a tissue in a mammal |
US5441944A (en) * | 1989-04-23 | 1995-08-15 | The Trustees Of The University Of Pennsylvania | Substituted cyclodextrin sulfates and their uses as growth modulating agents |
US5658894A (en) * | 1989-04-23 | 1997-08-19 | The Trustees Of The University Of Pennsylvania | Compositions for inhibiting restenosis |
US5874419A (en) * | 1989-04-23 | 1999-02-23 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulating growth of a tissue in a mammal |
EP0396184A3 (en) * | 1989-05-03 | 1992-05-20 | Janssen Pharmaceutica N.V. | Use of ketoconazole and a retinoid for the treatment of acne vulgaris |
EP0396184A2 (en) * | 1989-05-03 | 1990-11-07 | Janssen Pharmaceutica N.V. | Use of ketoconazole and a retinoid for the treatment of acne vulgaris |
AU648061B2 (en) * | 1990-01-29 | 1994-04-14 | Janssen Pharmaceutica N.V. | Improved cyclodextrin based erythropoietin formulation |
WO1991011200A1 (en) * | 1990-01-29 | 1991-08-08 | Janssen Pharmaceutica N.V. | Improved cyclodextrin based erythropoietin formulation |
FR2660309A1 (en) * | 1990-03-27 | 1991-10-04 | Roussel Uclaf | NOVEL COMPLEXES OF TIAPROFENIC ACID OR ITS INSOLUBLE OR PARTIALLY SOLUBLE ESTERS WITH CYCLODEXTRINS OR DERIVATIVES THEREOF. |
EP0449722A1 (en) * | 1990-03-27 | 1991-10-02 | Roussel-Uclaf | New complexes of tiaprofenic acid or its insoluble or partially soluble esters with cyclodextrines or their derivates |
US5332582A (en) * | 1990-06-12 | 1994-07-26 | Insite Vision Incorporated | Stabilization of aminosteroids for topical ophthalmic and other applications |
US5120720A (en) * | 1990-09-20 | 1992-06-09 | The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services | Preparation of lipophile:hydroxypropylcyclodextrin complexes by a method using co-solubilizers |
WO1992004888A1 (en) * | 1990-09-20 | 1992-04-02 | The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce | Preparation of lipophile: hydroxypropyl cyclodextrin complexes by a method using co-solubilizers |
US5776914A (en) * | 1991-09-19 | 1998-07-07 | The Trustees Of The University Of Pennsylvania | Prevention of hemolysis |
US5446030A (en) * | 1991-09-19 | 1995-08-29 | Weisz; Paul B. | Prevention of hemolysis |
CN1035923C (en) * | 1991-10-16 | 1997-09-24 | 先灵公司 | Lipophilic oligosaccharide antibiotics composite |
US5624914A (en) * | 1991-10-16 | 1997-04-29 | Schering Corporation | Lipophilic oligosaccharide antibiotic salt compositions |
WO1993007904A1 (en) * | 1991-10-16 | 1993-04-29 | Schering Corporation | Lipophilic oligosaccharide antibiotic salt compositions |
EP0538011A1 (en) * | 1991-10-16 | 1993-04-21 | Schering Corporation | Lipophilic oligosaccharide antibiotic salt compositions |
EP0539938A1 (en) | 1991-10-30 | 1993-05-05 | Schering Corporation | Tri-substituted tetrahydrofuran antifungals |
WO1993009114A1 (en) | 1991-10-30 | 1993-05-13 | Schering Corporation | Tri-substituted tetrahydrofuran antifungals |
US5670530A (en) * | 1992-10-26 | 1997-09-23 | Fuji Photo Film Co., Ltd. | Anti-cancer composition comprising rhodacyanine compound and cyclodextrin |
US5494901A (en) * | 1993-01-05 | 1996-02-27 | Javitt; Jonathan C. | Topical compositions for the eye comprising a β-cyclodextrin derivative and a therapeutic agent |
WO1994020091A1 (en) * | 1993-03-05 | 1994-09-15 | Hexal Pharma Gmbh | Crystalline cyclodextrin inclusion complexes of ranitidine hydrochloride and process for their preparation |
WO1994022455A1 (en) * | 1993-03-31 | 1994-10-13 | The Trustees Of The University Of Pennsylvania | Methods of affecting the growth of living tissue in mammals and compounds and compositions therefor |
WO1995005198A1 (en) * | 1993-08-17 | 1995-02-23 | Finn Molke Borgbjerg | Localanaesthetic preparation |
US5624940A (en) * | 1993-12-14 | 1997-04-29 | Eli Lilly And Company | Aqueous solution inclusion complexes of benzothiophene compounds with water soluble cyclodextrins, and pharmaceutical formulations and methods thereof |
US5646131A (en) * | 1994-02-22 | 1997-07-08 | The Arab Company For Drug Industries And Medical Applicances (Acdima) | Method for solubilizing drugs using cyclodextrins and carboxylic acids |
WO1995032737A1 (en) * | 1994-05-27 | 1995-12-07 | Farmarc Nederland Bv | Pharmaceutical composition |
US6566504B2 (en) | 1996-04-19 | 2003-05-20 | Alpha Therapeutic Corporation | Process for viral inactivation of lyophilized blood proteins |
BG64434B1 (en) * | 1997-03-26 | 2005-02-28 | Janssen Pharmaceutica Nv | Pellets containing core enveloped by intraconazol and polymer |
US6632803B1 (en) | 1997-06-21 | 2003-10-14 | Pfizer Inc | Pharmaceutical formulations containing voriconazole |
US6596706B1 (en) | 1997-11-07 | 2003-07-22 | Daiichi Pharmaceutical Co., Ltd. | Piperazine-cyclodextrin complexes |
EP1029872A4 (en) * | 1997-11-07 | 2001-05-02 | Daiichi Seiyaku Co | Piperazine-cyclodextrin complexes |
EP1029872A1 (en) * | 1997-11-07 | 2000-08-23 | Daiichi Pharmaceutical Co., Ltd. | Piperazine-cyclodextrin complexes |
US6485743B1 (en) | 1997-12-31 | 2002-11-26 | Choongwae Pharma Corporation | Method and composition of an oral preparation of itraconazole |
WO2000056336A3 (en) * | 1999-03-18 | 2000-11-16 | Knoll Ag | Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin |
WO2000056336A2 (en) * | 1999-03-18 | 2000-09-28 | Knoll Gmbh | Pharmaceutical compositions comprising a pyrimidine derivative and cyclodextrin |
WO2001001955A1 (en) * | 1999-07-02 | 2001-01-11 | Janssen Pharmaceutica N.V. | Nasal formulation of an antifungal |
WO2001014291A1 (en) * | 1999-08-24 | 2001-03-01 | Astrazeneca Ab | Use of cyclodextrin for protective storage of chemical compound libraries |
US6468989B1 (en) | 2000-07-13 | 2002-10-22 | Dow Pharmaceutical Sciences | Gel compositions containing metronidazole |
US6989381B2 (en) | 2000-08-22 | 2006-01-24 | Pharmacia Corporation | Solution composition of an oxazolidinone antibiotic drug having enhanced drug loading |
US7074824B2 (en) | 2001-07-31 | 2006-07-11 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
US6962944B2 (en) | 2001-07-31 | 2005-11-08 | Arqule, Inc. | Pharmaceutical compositions containing beta-lapachone, or derivatives or analogs thereof, and methods of using same |
US7348317B2 (en) | 2001-12-24 | 2008-03-25 | Dow Pharmaceutical Sciences | Aqueous compositions containing metronidazole |
WO2003075904A3 (en) * | 2002-03-07 | 2003-12-11 | Wrair | Cyclodextrin complexed artemisinins |
WO2003075904A2 (en) * | 2002-03-07 | 2003-09-18 | Wrair | Cyclodextrin complexed artemisinins |
US6818662B2 (en) | 2002-05-28 | 2004-11-16 | Taisho Pharmaceutical Co., Ltd. | Pharmaceutical composition |
WO2004000344A1 (en) * | 2002-06-24 | 2003-12-31 | Merck Patent Gmbh | Aqueous preparation containing oligopeptides and etherified cyclodextrin |
US7262165B2 (en) | 2002-06-24 | 2007-08-28 | Merck Patent Gmbh | Aqueous preparation containing oligopeptides and etherified cyclodextrin |
CN1294912C (en) * | 2004-03-01 | 2007-01-17 | 上海医药工业研究院 | Itraconazole hydrochloride composition and freeze-dried powder injection thereof |
US8859554B2 (en) | 2004-03-08 | 2014-10-14 | Boehringer Ingelheim Vetmedica Gmbh | Packaging assembly for pharmaceutical composition including pimobendan |
US8846680B2 (en) | 2004-03-08 | 2014-09-30 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical composition comprising pimobendan |
US8846679B2 (en) | 2004-03-08 | 2014-09-30 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical composition comprising pimobendan |
US8980894B2 (en) | 2004-03-25 | 2015-03-17 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure |
US9463199B2 (en) | 2004-03-25 | 2016-10-11 | Boehringer Ingelheim Vetmedica Gmbh | Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure |
US11413285B2 (en) | 2004-03-25 | 2022-08-16 | Boehringer Ingelheim Vetmedica Gmbh | PDE III inhibitors for treatment of asymptomatic heart failure |
US10537588B2 (en) | 2004-03-25 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size in mammals suffering from heart failure |
US10117869B2 (en) | 2004-03-25 | 2018-11-06 | Boehringer Ingelheim Vetmedica Gmbh | PDE III inhibitors for treatment of asymptomatic heart failure |
US9889148B2 (en) | 2004-03-25 | 2018-02-13 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size in mammals suffering from heart failure |
EP1637167A3 (en) * | 2004-09-16 | 2006-04-05 | Altergon S.A. | New injectable formulations containing progesterone |
EP1637167A2 (en) * | 2004-09-16 | 2006-03-22 | Altergon S.A. | New injectable formulations containing progesterone |
CN104857522A (en) * | 2004-09-16 | 2015-08-26 | 奥特昂股份有限公司 | Novel injectable formulations containing progesterone |
WO2006137433A1 (en) * | 2005-06-21 | 2006-12-28 | Wakamoto Pharmaceutical Co., Ltd. | Aqueous preparation having levocabastine solubilized therein |
JPWO2006137433A1 (en) * | 2005-06-21 | 2009-01-22 | わかもと製薬株式会社 | Aqueous drug with solubilized levocabastine |
WO2007038282A3 (en) * | 2005-09-26 | 2007-08-23 | B B Scient L L C | Stabilization of clostridium botulinum neurotoxin complex |
US7744904B1 (en) | 2005-09-26 | 2010-06-29 | B.B. Scientific L.L.C. | Stabilization of Clostridium botulinum neurotoxin complex |
US8641948B2 (en) | 2006-08-16 | 2014-02-04 | Novartis Ag | Method of making solid dispersions of highly crystalline therapeutic compounds |
EP2789349A1 (en) | 2006-11-07 | 2014-10-15 | Boehringer Ingelheim Vetmedica GmbH | Liquid preparation comprising pimobendan |
US10639305B2 (en) | 2006-11-07 | 2020-05-05 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising pimobendan |
US9107952B2 (en) | 2006-11-07 | 2015-08-18 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising pimobendan |
US9616134B2 (en) | 2006-11-07 | 2017-04-11 | Boehringer Ingelheim Vetmedica Gmbh | Liquid preparation comprising pimobendan |
WO2009107877A1 (en) * | 2008-02-28 | 2009-09-03 | Takeda Pharmaceutical Company Limited | Pharmaceutical composition |
US8664252B2 (en) | 2008-11-25 | 2014-03-04 | Boehringer Ingelheim Vetmedica Gmbh | Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy |
US9107919B2 (en) | 2009-02-06 | 2015-08-18 | Telormedix Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
US9066940B2 (en) | 2009-02-06 | 2015-06-30 | Telormedix, Sa | Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
CN102499909B (en) * | 2011-12-27 | 2013-08-07 | 哈尔滨三联药业有限公司 | Itraconazole dispersible tablets and preparation method thereof |
CN102499909A (en) * | 2011-12-27 | 2012-06-20 | 哈尔滨三联药业有限公司 | Itraconazole dispersible tablets and preparation method thereof |
US10398705B2 (en) | 2012-03-15 | 2019-09-03 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof |
KR20150129697A (en) * | 2013-03-13 | 2015-11-20 | 시애틀 지네틱스, 인크. | Cyclodextrin and antibody-drug conjugate formulations |
KR20210087560A (en) * | 2013-03-13 | 2021-07-12 | 씨젠 인크. | Cyclodextrin and antibody-drug conjugate formulations |
KR102401525B1 (en) * | 2013-03-13 | 2022-05-24 | 씨젠 인크. | Cyclodextrin and antibody-drug conjugate formulations |
US10071162B2 (en) | 2013-07-19 | 2018-09-11 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
US11185590B2 (en) | 2013-07-19 | 2021-11-30 | Boehringer Ingelheim Vetmedica Gmbh | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
EP3865120A1 (en) | 2013-07-19 | 2021-08-18 | Boehringer Ingelheim Vetmedica GmbH | Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition |
US10172804B2 (en) | 2013-12-04 | 2019-01-08 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical compositions of pimobendan |
US10874620B2 (en) | 2013-12-04 | 2020-12-29 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical compositions of pimobendan |
US10653633B2 (en) | 2013-12-04 | 2020-05-19 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical compositions of pimobendan |
US11298325B2 (en) | 2013-12-04 | 2022-04-12 | Boehringer Ingelheim Vetmedica Gmbh | Pharmaceutical compositions of pimobendan |
US10537570B2 (en) | 2016-04-06 | 2020-01-21 | Boehringer Ingelheim Vetmedica Gmbh | Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease |
CN112334494A (en) * | 2018-06-29 | 2021-02-05 | 罗盖特公司 | Novel hydroxypropyl-beta-cyclodextrin and method for producing the same |
FR3083234A1 (en) * | 2018-06-29 | 2020-01-03 | Roquette Freres | NOVEL HYDROXYPROPYL-BETA-CYCLODEXTRINS AND PROCESSES FOR THEIR PREPARATION |
WO2020002851A1 (en) * | 2018-06-29 | 2020-01-02 | Roquette Freres | NOVEL HYDROXYPROPYL-β-CYCLODEXTRIN AND PROCESS FOR THE PRODUCTION THEREOF |
CN114195733A (en) * | 2022-01-07 | 2022-03-18 | 华东理工大学 | Method for inhibiting isomerization of probenazole |
Also Published As
Publication number | Publication date |
---|---|
NL980009I1 (en) | 1998-05-06 |
CA1222697A (en) | 1987-06-09 |
EP0149197A3 (en) | 1985-08-14 |
ATE51145T1 (en) | 1990-04-15 |
DK175288B1 (en) | 2004-08-09 |
ZA8410042B (en) | 1985-09-25 |
HK131293A (en) | 1993-12-03 |
SG24893G (en) | 1993-08-06 |
AU3835285A (en) | 1985-07-12 |
CY1689A (en) | 1994-01-14 |
FI86140B (en) | 1992-04-15 |
DK359585A (en) | 1985-08-07 |
AU565966B2 (en) | 1987-10-01 |
DE3481680D1 (en) | 1990-04-26 |
HUT40561A (en) | 1987-01-28 |
HU200943B (en) | 1990-09-28 |
FI853198A0 (en) | 1985-08-20 |
EP0149197B2 (en) | 1997-01-08 |
FI853198L (en) | 1985-08-20 |
DK359585D0 (en) | 1985-08-07 |
NO2000007I1 (en) | 2000-09-21 |
JPH0570612B2 (en) | 1993-10-05 |
LU90283I2 (en) | 1998-11-03 |
EP0149197B1 (en) | 1990-03-21 |
EP0149197A2 (en) | 1985-07-24 |
FI86140C (en) | 1992-07-27 |
JPS61500788A (en) | 1986-04-24 |
DE3346123A1 (en) | 1985-06-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU565966B2 (en) | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation | |
US6407079B1 (en) | Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation | |
EP0197571B1 (en) | Novel derivatives of gamma-cyclodextrin | |
US4870060A (en) | Derivatives of γ-cylodextrin | |
US4727064A (en) | Pharmaceutical preparations containing cyclodextrin derivatives | |
US5324718A (en) | Cyclodextrin/drug complexation | |
EP1267941B1 (en) | Alprazolam inclusion complexes and pharmaceutical compositions thereof | |
KR100708360B1 (en) | Complex of Ras-Farnesyltransferase Inhibitor and Sulfobutylether-7-?-Cyclodextrin or 2-Hydroxypropyl-?-Cyclodextrin and Method | |
US6077871A (en) | Droloxifene pharmaceutical compositions | |
KR920008700B1 (en) | Process for preparing pharmaceutical preparation containing drugs which are instable or sparingly soluble in water | |
JPH07165616A (en) | Complex composition of cyclodextrin and method for making complex | |
HUT72055A (en) | Ciklodextrin-vinpocetin complexes process for producing them and pharmaceutical compositions containing them | |
NO171888B (en) | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL PREPARATION CONTAINING MEDICINAL SUBSTANCES WHICH ARE SOLELY SOLUBLE OR USTABILE IN WATER | |
FI86507B (en) | Method for the production of therapeutic compositions containing &gamma-cyclodextrin derivatives | |
CA2189863C (en) | Mucoadhesive emulsions containing cyclodextrin | |
IE80908B1 (en) | Derivatives of gamma-cyclodextrin | |
ZA200207221B (en) | Alprazolam inclusion complexes and pharmaceutical compositions thereof. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Designated state(s): AU DK FI HU JP KR NO US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 853198 Country of ref document: FI |
|
WWG | Wipo information: grant in national office |
Ref document number: 853198 Country of ref document: FI |